Researchers engineered a CRISPR-based cancer approach designed to selectively destroy targeted cells using a specialized “destroyer” enzyme concept rather than classic gene-editing. The work, published in Nature, centers on Cas12a2 derived from bacterial communities and described as acting as a suicide-like mechanism in response to viral detection. The strategy contrasts with standard CRISPR tools that function as editors “fixers” by modifying genetic material. In the reported approach, the enzyme is intended to shred genetic material in mutated or targeted cells to eliminate them. For the field, the implication is that CRISPR-derived modalities are moving beyond editing toward controllable cell-killing tools—an area of growing interest for oncology and potentially for difficult-to-treat solid tumors. If further validated, the platform could inform vector selection, dosing constraints, and safety engineering for next-generation CRISPR therapeutics.